Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
ADAM29 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 29 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ADAM29 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADAM28 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 28 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ADAM28 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADAM23 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 23 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ADAM23 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADAM21 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 21 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ADAM21 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADAM20 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 20 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ADAM20 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADAM2 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ADAM2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADAM18 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 18 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ADAM18 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADAM17 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 17 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ADAM17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADAM15 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 15 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ADAM15 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADAM11 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 11 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ADAM11 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADAM10 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 10 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ADAM10 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TNFSF9 Biologics Sequence Review Report 2026: Tumor necrosis factor ligand superfamily member 9 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of TNFSF9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.